To MUHC users: Please note that as of Dec 5, 2022, requests for outpatient antiviral management of COVID-19 for HIGH RISK patients should be directed to the ID-AMB (formerly MicroB/Lachine) service rather than ID-HOT. If a patient is a potential candidate for outpatient antiviral therapy but a delay is anticipated before they can be seen by Medical Day (eg. present to ED on a friday afternoon, weekend etc), please ensure that the antiviral is started in ED to ensure there are no delays in treatment! Prophylactic Evusheld should be offered to high-risk patients (see criteria) if > 6 months since their last dose.
top of page
Search
Recent Posts
See AllThe ASP chairs are happy to publish the MUHC ASP annual report 2022-2023, now available in the Resources section of the MUHC ASP website....
10
The ASP committee is happy to give you an early Christmas gift! We published the guidelines on management and treatment of Staphylococcus...
390
ASP committee developed a post-exposure prophylaxis (HIV, hepB & hepC) guidelines in collaboration with the CVIS team. It is available on...
200
bottom of page
Commenti